Elizabeth Masson-Hurlburt
Corporate Officer/Principal bei CORMEDIX INC.
Vermögen: 235 610 $ am 30.04.2024
Aktive Positionen von Elizabeth Masson-Hurlburt
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| CORMEDIX INC. | Corporate Officer/Principal | - | - |
| Technik-/Wissenschafts-/F&E-Leiter | 01.03.2018 | - |
Karriereverlauf von Elizabeth Masson-Hurlburt
Ehemalige bekannte Positionen von Elizabeth Masson-Hurlburt
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| NEUROBO PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.08.2016 | 01.03.2018 |
Ausbildung von Elizabeth Masson-Hurlburt
| Bay Path College | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 4 |
Operativ
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 1 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CORMEDIX INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Gemphire Therapeutics, Inc.
 Gemphire Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Gemphire Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics of dyslipidemia, as well as non-alcoholic fatty liver disease. It offers a small molecule formulated as a tablet product under the Gemcabene brand. The company was founded by Charles L. Bisgaier and David Lowenschuss on October 30, 2014 and is headquartered in Livonia, MI. | Health Technology |
